Swimmer’s plot of evaluable patients following tisagenlecleucel infusion and associated CRS/ICANS. Response to most recent therapy included in parentheses. 001 (fourth line; PR), 002 (third line; PD), 005 (fourth line; PR), 007 (fourth line; PD), 008 (second line; SD), 011 (fifth line; PD), 014 (sixth line; PD), 004 (fourth line; PD), 015 (sixth line; SD), 003 (fourth line; PD), 012 (fifth line; PD), and 009 (fourth line; PD). PD, progressive disease; PR, partial response; SD, stable disease. *Continued ibrutinib use through month 3.